Little is known about the aetiology of brain tumours. One putative factor suggested from animal models is a protective effect of dietary Zn. We tested the hypothesis that increased compared with low dietary Zn intake is protective against brain tumour development. We conducted a population-based case -control study in the UK, of adults aged 18-69 years, between 2001 and 2004 aiming to identify possible risk factors. Dietary information was collected from 637 cases diagnosed with a glioma or meningioma, and 876 controls. Data were obtained from a self-completed FFQ. Multivariate logistic regression analysis was conducted, adjusting for socio-demographic factors, season of questionnaire return, multivitamin supplementation and energy intake. Although a weak protective effect was observed for the third quartile of intake (normal compared with low intake) in the meningioma group, this was limited to the specific brain tumour subtype and quartile, and was not significant after also adjusting for intake of other elements. Overall there was no significant effect of Zn intake. No association or dose-response relationship was observed between increased compared with low Zn intake and risk of glioma or meningioma.
About 50 % of all primary brain tumours are gliomas and 25 % are meningiomas. Gliomas are of three main types (astrocytoma, ependymoma, oligodendroglioma) and are often associated with poor prognosis. Meningiomas are a usually benign type of brain tumour, but some can be 'atypical' and behave more aggressively 1 . A variety of risk factors for brain cancer have been investigated in epidemiological studies, but the evidence for environmental causation is inconsistent. Associations observed include certain medical conditions, exposures to radiation, viruses and chemicals 2, 3 . The relationship between dietary trace elements and adult brain tumour aetiology has not yet been fully investigated, as few studies involving trace elements have been conducted 2 
.
Zn is a trace element with antioxidant properties; such elements have been suggested 4 to be protective against brain tumour development. The main role of Zn is the maintenance of a healthy central nervous system. Zn is also important for DNA replication, protein synthesis and metabolism 5 and oxidative stress protection 6 . The present study was prompted by an a priori hypothesis suggested by animal models. In rat models, Zn is essential for good neuronal function 7 -9 . It has been shown that, in rat glioma cells 10 , increased oxidative stress occurs during Zn deficiency. Ho & Ames 10 also reported that, under low intracellular Zn status, proper DNA repair could not be achieved, and after Zn repletion DNA damage was reversed. Yousef et al. reported a significant increase in the levels of free radicals with Zn deficiency in the rat brain 11 . In addition, some human case -control studies have yielded inverse associations between Zn consumption and various cancers, such as oesophageal squamous cell carcinoma 12 and lung cancer 13 . Zn adjusted for Fe intake was inversely associated with upper digestive tract cancer in the follow-up Iowa Women's Health Study 14 . In contrast, a recent casecontrol study found that excessive Zn intake ($ 15·7 mg/d) increases prostate cancer risk in humans 15 . The concentration of Zn in the brain is higher than elsewhere in the body (about 150 mmol/l) 16 . Zn is most concentrated in neuron-abundant forebrain regions (for example, hippocampus) serving as an endogenous modulator in neurotransmission 17 . Excess excitation of Zn-containing neurons causes Zn decrease and neuronal damage. Dietary Zn deprivation may influence Zn balance in the brain, resulting in brain dysfunction 18 . Other dietary nutrients affect Zn concentrations in the brain and blood and, possibly, Zn availability for transport into the brain through the blood -brain barrier 19 . A number of nutrient elements, such as Ca, Fe, Cu and P, act as antagonists to Zn 20 , while other nutrients such as PUFA, fibre and protein facilitate Zn absorption 21, 22 , and some are able to cross the blood-brain barrier via different transport systems.
The present study investigated the a priori hypothesis that higher dietary Zn levels may be associated with a decreased risk of brain tumour development in a large populationbased case -control study 23 .
Subjects and methods
The Participants were interviewed using a computer-assisted personal interview system, and then given a FFQ to complete and return by post. Information was collected on dietary intake and use of vitamin, mineral and other dietary supplements. The FFQ includes questions on the average consumption frequency of a medium portion of 132 food items (the most commonly consumed in this population). The subjects were asked about their usual diet during the 2 years preceding diagnosis, to reduce the possibility of reverse causation. Consumption frequency categories varied from 'six or more per day to 'never or less than once per month'.
Data analysis
Average daily nutrient intake was calculated by multiplying the daily consumption frequency of each food item by the content of the examined nutrient in the respective food item obtained from food composition tables 24 . Data were then processed by the nutritional software based on the program used for the European Prospective Investigation into Cancer (EPIC) study.
Dietary Zn intake was adjusted for energy intake using the residual method 25, 26 and intake levels were defined by quartiles of the control distribution (lowest category used as the reference group).
Standard unconditional logistic regression was used to estimate OR and 95 % CI in univariate and multivariate analyses, for gliomas and meningiomas separately. All controls were used in the analyses, as in a previous analysis from the UKABTS on the association between the use of mobile phones and risk of developing brain tumours 23 . In addition to sex, age (in 5-year groups) and region, the multivariate standard logistic regression adjusted simultaneously for the following variables: deprivation category (Townsend score reflecting social class) 27 , season of dietary questionnaire return, multivitamin supplement use and energy intake 28 (pp. 288-291). Because energy intake may be an important disease predictor, it was included in the regression model together with the nutrient energy-adjusted term 28 (pp. 288-291).
Subjects' intake of other nutrients besides Zn was also assessed and included as terms in the regression analysis. The literature suggests that nutrients having a biological relevance to Zn are the following: Ca, Fe, Cu, P (the main Zn antagonists), PUFA, protein and dietary fibre (the last three are thought to affect Zn absorption and amounts in the body, for example, protein promotes Zn absorption). These were tested for interaction with Zn, by including interaction terms in the model. Nutrients were also assessed for confounding. In the regression analysis, non-significant nutrient terms were taken out of the model, also provided that excluding them did not largely inflate the standard error while changing very little the corresponding effect size of the examined variable (Zn intake). Presented results are those obtained with inclusion of only those nutrients that remained significant.
Data analysis was carried out using the SPSS statistical package (version 11.5; SPSS, Inc., Chicago, IL, USA). All presented P values are two-sided.
Ethical approval
Approval has been obtained from multi-centre research ethics committees (MREC/99/0/77) and all relevant local research ethics committees.
Results
Of those who returned an FFQ, 637 cases (436 gliomas, 201 meningiomas) and 876 controls were included in the analyses, after fifteen subjects (eleven cases, four controls) were excluded as their energy intake and BMI were incompatible. Table 1 gives the response rates -for the dietary FFQ -of cases and controls grouped by tumour type. Table 2 presents the demographic and social characteristics of subjects who returned the dietary FFQ. Table 3 shows the results of analysis by brain tumour subtype. For glioma, no association was seen with Zn before or after adjustment for confounders. A statistically significant risk reduction for meningioma was observed only in the 3rd quartile of dietary Zn intake (adjusted OR 0·62 (95 %CI: 0·39, 0·99); P¼0·048). The crude results were not significant.
For nutrients biologically relevant to Zn as suggested from the literature (Ca, Fe, Cu, P, PUFA, protein and fibre), interaction terms were included in the analysis. However, all interaction terms were found to have non-significant overall P values. The above nutrients were also assessed for confounding, and those significant were entered in the regression analysis.
Confounders remaining significant when examining the Zn-disease association were Fe for gliomas and Cu for meningiomas (overall significance P¼0·05 and P¼0·02 respectively). Results appear in Table 4 . Zn intake was significantly correlated with both Cu intake and Fe intake at the P, 0·01 level (the Pearson correlation coefficient between Zn and Fe intake for gliomas was 0·25, and between Zn and Cu intake for meningiomas was 0·27). However, strong collinearity was not observed in the data, as collinearity tests conducted were not significant (gliomas R 2 0·05; meningiomas R 2 0·13). Note that, after taking account of Cu intake in the analysis for meningiomas, the result for the 3rd quartile was no longer statistically significant (Tables 3 and 4) . We also obtained results for groupings of tertiles according to the RDA recommendations for Zn (8 -11 mg/d). Results were similar to those already obtained (before adjustment, P gliomas ¼ 0·561, P meningiomas ¼ 0·125; after adjustment for Fe, Cu respectively, P gliomas ¼ 0·577, P meningiomas ¼ 0·224) and no significant associations were observed. Additional adjustment of Zn intake quartiles for dietary intake of vitamins A (carotene), B 12 , B 6 , C, D, E, biotin, niacin, retinol, riboflavin and thiamin did not alter any of the results.
Discussion
Zn is involved in cell division and differentiation, in tumour cell metabolism 5 , and in the normal development of natural killer cells 29 . Normal Zn levels work against superoxide free radicals 29, 30 , and it is often suggested that free radical reduction may help to lower cancer risk 31, 32 . Zn deficiency is prevalent in some cancers, and low Zn levels may reduce the number of helper T-cells and thymic hormone levels 33 , thereby weakening immune function 29 . Cancer, in general, arises more frequently against a background of immunodeficiency 33 .
On the other hand, in animal models with existing tumours, depletion of dietary Zn has been proven to suppress tumour growth 34, 35 . Excess Zn intake has been linked to disease and toxicity 31 . Reduced immune function can result from both excessive Zn intake 36 and low Zn intake, as mentioned earlier. The above contradicting evidence shows that the mechanisms behind the Zn intake -brain tumour relationship are not yet fully comprehended; thus, a balanced intake is recommended 37 . Blood-brain barrier dysfunction has been linked to neurological conditions and brain tumour development, i.e. the barrier is usually non-existent in brain tumours 38 . Intake of normal Zn levels is required for a healthy blood-brain barrier 19 , as enhanced dietary Zn consumption does not affect Zn concentration in the brain except for the case where Zn deprivation already exists 18 .
Results of a recent study show that Zn depletion damages non-brain endothelial cells; however, the brain endothelial cells respond by enhancing barrier property 39 . Levels of other elements in the brain play an important role, as interaction with elements transported across the blood-brain barrier affects Zn absorption and its concentrations in the brain and, subsequently, its contribution to normal brain function. Fe and Cu are both elements that can pass through the blood-brain barrier and affect Zn levels 20 . Fe is transported through the barrier by p97 40 and Cu via a Cu-transporting ATPase mechanism 41 .
Potential areas of bias
Participation levels were relatively low amongst cases. This was due mainly to disease severity; patients were very ill or died before being recruited. As reported previously 23 , highgrade glioma cases were less likely to be interviewed than those diagnosed with a low-grade tumour. Control Q, quartile. * Significant at P,0·05 level; two-tailed P value. † Adjusted for age (in 5-year groups), sex, study region, deprivation category (Townsend score), season of FFQ return and multivitamin supplementation. Table 4 . Association between dietary zinc intake and gliomas and meningiomas adjusted for iron and copper intake respectively (Odds ratios and 95 % confidence intervals) 2·2 -9·1  129  219  1·00  Q2: 9·2 -10·3  101  219  0·92  0·65, 1·31  0·645  Q3: 10·4 -12·0  96  221  0·88  0·62, 1·25  0·480  Q4: 12·1 -21·9  110  217  0·96  0·68, 1·34  0·797  P for trend  0·749  Meningioma  201{  876  Zn (mg/d)  0·526  Q1: 1·1 -8·8  61  219  1·00  Q2: 8·9 -10·0  48  219  0·88  0·55, 1·40  0·593  Q3: 10·1 -11·6  45  219  0·70  0·43, 1·14  0·147  Q4: 11·7 -21·4  47  219  0·79  0·48, 1·29  0·345  P for trend  0·242 Q, quartile. * Two-tailed P values; P,0·05 significance level. † Energy-adjusted mean intake of Fe and Cu was 28·82 and 2·42 mg respectively for controls. ‡ For glioma, adjusted for age (in 5-year groups), sex, study region, deprivation category (Townsend score), season of FFQ return, multivitamin supplementation and Fe intake. § For meningioma, adjusted for age (in 5-year groups), sex, study region, deprivation category (Townsend score), season of FFQ return, multivitamin supplementation and Cu intake. k Energy-adjusted mean Fe intake for glioma cases was 27·19 mg. { Energy-adjusted mean Cu intake for meningioma cases was 2·46 mg. participation was also low, a problem for many populationbased studies 28 (pp. [9] [10] [11] [90] [91] . This may have introduced selection bias amongst controls, as previously reported controls taking part in the study tended to be more affluent than non-interviewed controls 23 . Controls used may have better nutritional regimens than the general population. Deprivation category was adjusted for in the analysis, although the bias cannot be fully removed.
The FFQ method is cheap, easy to administer, and provides quick intake estimates 28 (pp. 74-91). Although extreme misclassification has been shown to be minimal 42 , another problem associated with use of FFQ in case -control studies is that questions may have been misinterpreted by some subjects 28 (pp. 101-124, 302-304). Energy adjustment, as carried out in the present study, minimises errors resulting from general food consumption over-or under-reporting 25 . The dietary FFQ used (based on the EPIC FFQ) containing questions on as many as 132 food items commonly consumed in the UK might also have reduced underreporting of food consumption 42 .
In the study, the frequency question was combined with a specific 'medium portion' size and this can present cognitive challenges for subjects 43 . However, several studies have found that consumption frequency is the main determinant of between-person variation in measured dietary intake levels and that it is positively correlated with portion size 43 .
There is concern that cases will report on their diets differently to controls 44 . Brain tumours are associated with impaired memory and concentration 45 and current dietary habits also considerably affect responses regarding previous diet 42 . However, recall bias is reduced by recruiting incident cases 28 (pp. 153-155), as has been done in the present study.
Missing values
The suggestive result before Cu inclusion could potentially be stronger, as dietary assessment through FFQ inherently produces measurement error and generally modest relative risks 28 . In that respect, missing values are potentially a source of bias in the present study. Some foods (for example, cooked vegetables), tend to be more frequently omitted than others 28 (pp. 61 -67) and respondents tend to selectively omit foods they never or seldom eat 46 . After conducting a missing values analysis, we found that there were significantly more missing values for cases than controls. Also, responses on Zn-containing foods are different from those on food items containing Cu. Of missing values for Zn, 64 % are for foods with zero Zn content; the respective percentage for Cu is 56 %. Although Cu has 4 % of its missing values for foods containing 5·8 -9·9 mg Cu (the highest composition range), the highest percentage (22 %) of missing values is accumulated in the 0·01 -0·09 mg range (lowest). However, the highest percentage (31 %) of missing values for Zn is found in the 0·1 -1·0 mg range. Therefore, more of the missing values for Zn are for foods with a moderate composition of Zn, while more of the missing values for Cu are for foods low in Cu, indicating that Zn intake may have been underestimated. It would be interesting to see if Zn amounts greater than used here would yield an effect.
Conclusions
In this dietary investigation of the UKABTS, no associations were found between dietary Zn intake and risk of glioma or meningioma. Overall, our findings are non-significant. The specific hypothesis on a protective effect of increased compared with low levels of dietary Zn against glioma or meningioma formation is not supported.
There is no strong multi-collinearity in the data. Therefore, controlling for a confounding effect of Fe and Cu intake is helpful, as relationships of dietary elements are complex and it is difficult to separate the effects of one element alone from the effects of others. 
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